SHPH earnings analysis
What we found in SHPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Shuttle Pharmaceuticals Holdings, Inc. continues to face operational challenges with a reported net loss of $2.15 million for Q1 2026, which marks a 29% improvement from the previous year. The company has completed an equity financing round, generating $3.2 million in net proceeds, aiding its liquidity position amidst ongoing financial difficulties.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Improvement
- The net loss decreased by $0.9 million, or 29%, from $3.05 million in Q1 2025 to $2.15 million in Q1 2026.
- Significant R&D Expense Reduction
- Research and development expenses fell by 83%, from $1.57 million in Q1 2025 to $0.27 million in Q1 2026.
- Increased General & Administrative Costs
- General and administrative expenses rose by 94%, from $0.60 million in Q1 2025 to $1.16 million in Q1 2026.
- Positive Working Capital Movement
- The working capital deficit improved by $1.62 million, from $(7.46) million as of December 31, 2025 to $(5.84) million by March 31, 2026.
- Successful Equity Financing Accomplished
- Raised approximately $3.2 million in net proceeds from an equity financing that closed in March 2026.
- Cash Utilization Slightly Optimized
- Cash used in operating activities decreased from $2.53 million in Q1 2025 to $2.42 million in Q1 2026, a 4% improvement.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- The company incurred a net loss of $2.15 million and has not generated any revenue during the quarter.
- Significant Working Capital Deficit
- As of March 31, 2026, the working capital deficit stood at $(5.84) million, raising substantial doubt about the company's ability to continue as a going concern.
- Dependence on Additional Financing
- The company's viability depends on successfully raising further equity or debt financing to fund ongoing operations.
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SHPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever